London, ON, CANADA, Release: August 18, 2022 Alimentiv Health Trust is pleased to announce the appointment of Dr. Amara Siva, Mr. John Fox and Mr. Paul Rothwell to the Alimentiv Holdings Board of Directors.
“We are pleased to welcome Amara, John and Paul to the Alimentiv Holdings Board”, said Jeff Smith, CEO Alimentiv Inc. and Director AcelaBio. “The collection of deep business, scientific, technology and laboratory operations expertise that Amara, John and Paul bring will enhance the strength of our board and further support our companies as we grow in pursuit of our mission to transform human health.”
Dr. Siva is an operations executive with over 20 years of molecular diagnostic experience, including assay development from concept stage to clinical validation. Dr. Siva is currently Vice President, Laboratory Operations at Epic Sciences where she heads clinical testing operations for the CAP/CLIA, translational research, and manufacturing/tech transfer laboratories.
In addition to her corporate positions, she has served on the Governing and Editorial Boards for the Malki Museum, California’s first museum founded by Native Americans, as well as the Board of Advisors for other non-profit organizations.
John J. Fox is a retired former Vice President with Johnson & Johnson. His last assignment was managing all aspects of Global Payroll, HR Services and related finance functions.
Over the years, John built a strong reputation as an active business partner supporting the supply chain, research and development, sales and marketing, and administration areas of the business.
Paul is co-founder and CEO of Onebridge, a data and analytics consulting company focused on helping companies of all sizes turn their data into decision intelligence.
Prior to Onebridge, Paul spent over 10 years in sales and leadership roles with various information technology companies across the Midwest. He currently serves on the board of numerous non-profits and is active in his local community.
With the announcement of new board appointments, Alimentiv Holdings would also like to recognize the contributions of retiring board members, Paul Knill and Dr. Stephan Targan, whose board terms have concluded. Jennifer Roedding, incoming Chair of Alimentiv Holdings said, “As we welcome our three new board members, we also wish to express our gratitude to Paul and Steph for their outstanding contributions to our board and their unwavering commitment to our mission”.
Dr. Stephan Targan joined Alimentiv’s Board of Directors in 2018 and supported Alimentiv through the early days of its transition from Western University. His breadth of entrepreneurial, scientific and start-up experience helped accelerate the growth of Alimentiv’s precision medicine business and brought valuable insights that led to the successful launch of Alimentiv’s second company AcelaBio, a state-of-the-art research and precision medicine laboratory.
Paul Knill served on the Board of Directors as the Board’s chair since the inception of Robarts Clinical Trials Inc. under Western University. Paul’s steady presence and counsel to the board and leadership team provided enormous value. He supported the organization through several important milestones including its transition from Western University, the rebranding of the CRO from Robarts Clinical Trials to Alimentiv Inc. and the launch of its second company AcelaBio. Alimentiv will continue to benefit from Paul’s steady leadership and counsel as he will remain a Trustee of Alimentiv Health Trust.
Fern Livingstone, Senior Manager, Marketing & Sales
Tel: (519) 639-3205
About the Alimentiv Health Trust
Companies under the Alimentiv Health Trust are commercial ventures driven by the Evergreen principles of purpose, people first, and long-term profitable growth.
Alimentiv (CRO) is a global research organization providing clinical trials, central image management, and precision medicine services to the pharmaceutical and biotechnology industries. Headquartered in London Ontario, Alimentiv employs approximately 400 people across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. Its unique model combines the efforts of leading, internationally recognized academic researchers with operational experts to offer integrated solutions to its customers. Founded in 1986 at the Robarts Research Institute, the clinical trials division was initially led by Dr. Henry Barnett. In 1997, Dr. Brian Feagan, Professor of Medicine, Epidemiology & Biostatistics at Western University assumed leadership and built upon the foundation of academic excellence by focusing the organization on Inflammatory Bowel Disease (IBD) research. Over the past 20 years, Alimentiv has become recognized as an expert in clinical trial design, central image management solutions, outcome measure development, and precision medicine for drug development in IBD. Today, Alimentiv provides services in over 60 countries worldwide, collaborates with leading academic research institutions across the globe, and partners with many of the leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients.
About Alimentiv Inc.
Alimentiv is a global contract research organization (CRO) providing clinical trials, central image management, precision medicine and real world evidence services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 450 people across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. The unique model of the organization combines the efforts of internationally recognized academic researchers and operational experts to offer integrated solutions to customers. Founded in 1986 at the Robarts Research Institute, the clinical trials division was initially led by Dr. Henry Barnett. In 1997, Dr. Brian Feagan, Professor of Medicine, Epidemiology & Biostatistics at Western University assumed leadership and built upon the foundation of academic excellence by focusing the organization on Inflammatory Bowel Disease (IBD) research. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, central image management solutions, outcome measure development, and precision medicine for drug development in IBD. Today, Alimentiv provides services in more than 50 countries worldwide, collaborates with leading universities and academic institutions across the globe, and partners with many of the leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients.
Alimentiv is committed to medical research and development, with a focus on identifying barriers to drug development and pursuing solutions that advance IBD research. The research findings are operationalized into efficient clinical trial methodology for clients that is in-line with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation, and standardization of the outcome measures and technology that are shaping the evolving clinical trial landscape for multiple indications and providing meaningful long-term consequences for patients, their treatment, and for society. For more information visit: www.alimentiv.com
About AcelaBio (US) Inc.
AcelaBio (US) Inc. is a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for GI global clinical trials. It is wholly owned by the Alimentiv Health Trust and was created to meet the growing clinical research demand for quality and efficiency in laboratory service.
The state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research to accelerate biomarker discovery and development. AcelaBio employs medical, scientific, and operational experts who are dedicated to delivering reliable, high-quality data and digital pathology. By investing in people, facilities, and technology, AcelaBio provides end-to-end histopathology and precision medicine services that meet today’s and tomorrow’s regulatory standards to support the development of safe and effective therapies for patients.